Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Amgen

Status and phase

Completed

Phase 3

Conditions

Ulcer

Treatments

Drug: Ibuprofen/famotidine

Drug: Ibuprofen

Study type

Interventional

Funder types

Industry

Identifiers

NCT00450216

HZ-CA-303

Details and patient eligibility

About

The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.

Full description

HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. The study is designed to determine whether the combination product reduces the rate of ulcer development in subjects who require long-term daily use of ibuprofen.

Subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a 24 week treatment period or until they develop either an endoscopically-diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Subjects will visit the study center for Screening and at Weeks 4, 8, 16, and 24. Physical exams will be performed, and clinical laboratory measurements made, at selected times during the study. Endoscopic exams will be performed during Screening and at Weeks 8, 16, and 24. Subjects will be contacted four weeks following study completion.

Study with completed results acquired from Horizon in 2024.

Enrollment

906 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Expected to require daily administration of an NSAID for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain.
Did not use a NSAID within the 30 days prior to study entry

Exclusion criteria

History of erosive esophagitis
History of any of the following serious gastrointestinal complications:
- perforation of ulcers,
- gastric outlet obstruction due to ulcers, or
- gastrointestinal bleeding.
Active cardiac, renal, and/or hepatic disease
Current Helicobacter pylori (H. pylori) infection
Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin within the 14 days prior to study entry.
Uncontrolled diabetes
Uncontrolled hypertension
Positive pregnancy test at screening
Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
Currently participating, or participation within 30 days prior to study entry, in an investigational drug study